Clinical Trial Update: Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the combination of empagliflozin and linagliptin versus linagliptin alone over 24 weeks in adults with Type 2 diabetes. The study assess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin)
• Tradjenta (Linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2016-04-18